Last updated: October 28, 2026
Antihemophilic factor (recombinant), single chain is marketed as Afstyla by CSL Behring. It is a recombinant factor VIII therapy for hemophilia A, differentiated by a covalently linked single-chain structure that improves molecular stability and supports dosing at intervals comparable to other extended-half-life factor VIII products. Its commercial trajectory depends on conversion from standard half-life factor VIII, competition from extended-half-life products, non-factor prophylaxis with Hemlibra, gene therapy, and hospital and specialty-pharmacy reimbursement.
CSL does not separately disclose Afstyla revenue in its public financial statements. The product remains commercially relevant within CSL Behring's broader hemophilia portfolio, but its sales contribution cannot be isolated from the company's disclosed segment results.
What is antihemophilic factor recombinant single chain?
Afstyla is a recombinant coagulation factor VIII product consisting of a single-chain factor VIII molecule. The single-chain design links the heavy and light chains through a covalent bond, improving structural integrity compared with conventional two-chain factor VIII products.
| Attribute |
Afstyla |
| Active ingredient |
Recombinant factor VIII, single chain |
| Brand owner |
CSL Behring |
| U.S. approval |
2016 |
| Primary indication |
Congenital hemophilia A |
| Therapeutic class |
Recombinant factor VIII replacement |
| Administration |
Intravenous |
| Clinical use |
On-demand treatment, perioperative control, routine prophylaxis |
| Patient segment |
Previously treated patients, including adults and children |
| Biological half-life |
Approximately 14 to 15 hours, subject to patient variation |
| Regulatory category |
Biologic |
| Biosimilar pathway |
FDA biosimilar pathway under the Public Health Service Act |
The product is used to replace deficient factor VIII and restore thrombin generation. It does not treat inhibitors against factor VIII. Patients who develop inhibitors may require bypassing agents or non-factor therapies.
How does Afstyla compare with competing factor VIII products?
Afstyla competes in a mature factor VIII market that has shifted from standard half-life replacement toward extended-half-life products and non-factor prophylaxis.
| Product |
Company |
Technology or positioning |
Approximate half-life positioning |
Main competitive issue |
| Afstyla |
CSL Behring |
Single-chain recombinant factor VIII |
Extended relative to standard products |
Competes with longer-acting factor VIII and Hemlibra |
| Advate |
Takeda |
Standard recombinant factor VIII |
Standard half-life |
Established physician and patient familiarity |
| Eloctate |
Bioverativ/Sanofi |
Fc-fusion factor VIII |
Extended half-life |
Strong prophylaxis positioning |
| Jivi |
Bayer |
PEGylated recombinant factor VIII |
Extended half-life |
Competes on reduced dosing frequency |
| Esperoct |
Novo Nordisk |
GlycoPEGylated factor VIII |
Extended half-life |
International commercial presence |
| Kovaltry |
Bayer |
Standard recombinant factor VIII |
Standard half-life |
Price and established use |
| Altuviiio |
Sanofi |
EHL factor VIII with XTEN technology |
Longer-acting than many earlier EHL products |
Raises the efficacy and dosing-frequency benchmark |
| Hemlibra |
Roche |
Bispecific non-factor therapy |
Subcutaneous prophylaxis |
Reduces reliance on factor VIII replacement |
| Roctavian |
BioMarin |
Adeno-associated virus gene therapy |
One-time gene therapy approach |
Long-term durability, eligibility, and reimbursement uncertainty |
Afstyla's single-chain structure provides a product-level differentiation, but the commercial advantage is narrower than a major shift in dosing frequency. Physicians often select factor VIII products based on bleeding control, pharmacokinetics, inhibitor history, infusion burden, formulary access, and patient preference.
What is the FDA regulatory status of Afstyla?
The FDA approved Afstyla in 2016 for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis in adults and children with hemophilia A. The FDA label includes pharmacokinetic and clinical data supporting use in previously treated patients.
The product is not interchangeable with Hemlibra because Hemlibra is a non-factor therapy with a different mechanism, administration route, and clinical monitoring framework. Afstyla also is not interchangeable with other factor VIII products without clinical oversight.
The main regulatory risks are:
- Anti-drug antibodies and factor VIII inhibitors.
- Product-specific immunogenicity monitoring.
- Pediatric and surgical-use requirements.
- Manufacturing consistency for a complex recombinant protein.
- Label competition from products with less frequent administration.
- Reimbursement restrictions affecting prophylaxis uptake.
What patents protect recombinant single-chain factor VIII?
Afstyla is protected through a combination of composition, protein-engineering, formulation, manufacturing, and use-related intellectual property. The commercial product is a biologic, so its patent position is not presented through the small-molecule Orange Book framework.
The core patent categories are:
- Single-chain factor VIII molecules.
- Covalent linkage between factor VIII domains.
- Stabilized recombinant factor VIII constructs.
- Cell-culture and purification processes.
- Formulations that preserve activity during storage and reconstitution.
- Treatment and prophylaxis methods using the engineered factor VIII.
- Device, vial, and administration systems where separately protected.
A definitive product-specific patent table requires matching CSL's patents, licensed rights, terminal disclaimers, patent-term adjustments, and jurisdiction-specific prosecution histories to the marketed Afstyla formulation. Public FDA biologic records do not provide a single authoritative expiration date for the complete commercial patent estate.
Does Afstyla have Orange Book-listed patents?
Afstyla does not have a conventional Orange Book patent listing comparable to a small-molecule drug. FDA biologics are generally evaluated through the Purple Book and the Biologics Price Competition and Innovation Act framework.
Patent information may exist in USPTO records, litigation filings, licensing agreements, and company disclosures. The absence of an Orange Book entry does not mean the product lacks enforceable patent rights. It means the Orange Book is not the primary public register for the product's biologic patent position.
When does Afstyla lose exclusivity?
Afstyla's regulatory exclusivity is separate from patent exclusivity.
Under the U.S. biologics framework, a reference biologic generally receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules and regulatory interpretation. Afstyla's 2016 approval therefore placed the end of the 12-year period around 2028, although the precise calculation depends on the statutory first-licensure date and any relevant legal determinations.
The practical loss-of-exclusivity timeline has several layers:
| Exclusivity layer |
Afstyla implication |
| FDA reference-product exclusivity |
Approximately 12 years from first licensure, subject to statutory calculation |
| Patent exclusivity |
Depends on issued claims, patent-term adjustment, terminal disclaimers, and jurisdiction |
| Manufacturing protection |
May delay competition where process complexity creates a technical barrier |
| Market exclusivity |
Can persist after initial biosimilar entry through contracting and switching friction |
| Clinical differentiation |
May support pricing after patent expiry if physicians value the product profile |
A biosimilar applicant could pursue FDA approval before the end of reference-product exclusivity, but commercial launch would remain constrained by regulatory exclusivity, patent rights, settlement terms, and litigation outcomes.
What biosimilar and generic entry risks exist for Afstyla?
Traditional generic entry is not the relevant pathway. Afstyla is a complex biologic, so competition would likely come from biosimilars or other recombinant factor VIII products.
Biosimilar risk
Biosimilar development for factor VIII faces several barriers:
- Complex protein structure and post-translational modification.
- Need to establish high similarity without clinically meaningful differences.
- Assays for potency, glycosylation, impurities, and clotting activity.
- Immunogenicity and inhibitor assessment.
- Manufacturing-scale validation.
- Physician and patient confidence in switching.
- Contracting with specialty distributors and hemophilia treatment centers.
The biosimilar risk is therefore lower than the risk from branded therapeutic substitution by Hemlibra or newer factor VIII products. A biosimilar could pressure price and formulary positioning, but it would not automatically displace Afstyla in all patients.
Non-factor competition
Hemlibra is the most important structural competitor because it provides subcutaneous prophylaxis and reduces dependence on intravenous factor replacement. Hemlibra has expanded the treatment options for patients who prioritize lower administration burden, including patients with and without inhibitors.
Altuviiio raises a separate competitive risk by offering longer dosing intervals than many earlier factor VIII products. Its commercial impact is greater in patients who remain committed to factor replacement but want fewer infusions.
What is the financial trajectory of Afstyla?
CSL reports financial results by business segment rather than by individual product. Its annual reports disclose CSL Behring revenue and business performance but do not provide a separate Afstyla sales line. A precise product-level revenue series, margin profile, or growth rate therefore is not publicly established in CSL's audited reporting.
The likely financial trajectory has four stages:
2016 to approximately 2019: launch and adoption
Afstyla entered a market dominated by established factor VIII brands. Initial adoption depended on conversion from other recombinant factor VIII products, hospital and hemophilia-treatment-center protocols, and evidence supporting prophylaxis in pediatric and adult patients.
2020 to 2022: portfolio competition
The product faced greater pressure from Hemlibra and other extended-half-life factor VIII products. The COVID-19 period also increased the commercial value of products that reduced infusion frequency and supported home treatment, although patient access and treatment-center activity varied by geography.
2023 onward: mature branded competition
Afstyla operates in a mature market with several competing products and stronger payer scrutiny. Growth is more likely to come from share retention, geographic expansion, and selected patient conversion than from broad category expansion.
Around 2028 and later: exclusivity transition
The reference-product exclusivity window approaches its statutory end around 2028. The commercial effect will depend on biosimilar timing, patent litigation, settlement agreements, payer adoption, and the extent to which Afstyla retains clinical preference.
How much revenue is exposed to Afstyla competition?
Afstyla-specific revenue exposure is not separately disclosed. The relevant financial exposure is CSL Behring's broader hemophilia franchise, which includes multiple products and is reported within CSL's specialty pharmaceutical operations.
Revenue pressure can arise through:
- Switching to Hemlibra.
- Switching to newer extended-half-life factor VIII products.
- Payer-mandated product preference.
- Biosimilar price competition.
- Reduced use of intravenous replacement after gene therapy.
- Lower annual factor consumption in patients achieving stable prophylaxis.
- Contracting concessions required to preserve formulary access.
The risk is material at the franchise level but cannot be quantified accurately at the Afstyla product level using CSL's public segment reporting.
What manufacturing and intellectual-property barriers protect Afstyla?
Manufacturing is a meaningful barrier even after core patents expire. Recombinant factor VIII production requires controlled cell-line development, viral safety controls, purification, formulation, fill-finish, and validated potency assays.
The single-chain structure adds technical complexity because the manufacturer must consistently control:
- Correct chain linkage.
- Protein folding and molecular integrity.
- Factor VIII activity.
- Aggregation and degradation.
- Host-cell proteins and process impurities.
- Stability during storage and reconstitution.
These barriers support continued market presence after patent expiry, but they do not prevent well-funded biologic manufacturers from developing competing products.
Which companies are most likely to challenge Afstyla?
Potential competitors include established factor VIII manufacturers and biologic developers with protein-engineering capabilities. The most credible competitive groups are:
- Sanofi, through Eloctate and Altuviiio.
- Roche, through Hemlibra.
- Takeda, through Advate and other hemophilia products.
- Bayer, through Kovaltry and Jivi.
- Novo Nordisk, through Esperoct and its broader hemophilia portfolio.
- Specialist biosimilar developers with recombinant protein manufacturing capacity.
A direct biosimilar challenge to Afstyla would face more technical differentiation than a biosimilar challenge to a conventional factor VIII product because the reference molecule's single-chain architecture would need to be closely characterized.
What patent litigation and settlement issues affect Afstyla?
No single publicly established litigation event defines Afstyla's current commercial position. The principal legal issues are likely to involve:
- Validity and scope of engineered factor VIII claims.
- Ownership and licensing of single-chain technology.
- Patent-term adjustment and expiration calculations.
- Process patents covering cell culture or purification.
- Biosimilar notice and launch timing.
- Settlement agreements that restrict launch dates.
- Regulatory exclusivity under the BPCIA.
Any future biosimilar litigation would likely proceed through patent exchanges, federal district court actions, and potentially Federal Circuit review. Settlement terms could establish a launch date earlier than the latest asserted patent expiration while preserving some period of branded market protection.
How strong is the Afstyla patent estate?
The estate appears strongest where claims cover the specific single-chain molecule, validated structural characteristics, or manufacturing steps that are difficult to design around. Method-of-use claims are generally less durable than composition claims because biosimilar developers may challenge claim scope, validity, or non-infringement.
The commercial strength of the estate depends on:
- Number of unexpired composition claims.
- Patent-term adjustment.
- Geographic coverage.
- Whether claims cover the marketed product rather than an earlier construct.
- Availability of non-infringing manufacturing alternatives.
- Patent ownership and licensing chains.
- Litigation history and claim construction.
The absence of a conventional Orange Book listing makes public launch-risk analysis less straightforward than for small-molecule products.
What generic launch scenarios are most likely?
Scenario 1: No near-term biosimilar launch
Afstyla retains share through contracting, physician familiarity, and manufacturing complexity. Competition comes mainly from Hemlibra and newer factor VIII products.
Scenario 2: One biosimilar entrant
A single biosimilar pressures net price but does not eliminate the product. CSL responds through rebates, contracting, patient-support services, and selective price defense.
Scenario 3: Multiple biosimilar entrants
Price erosion accelerates, particularly in payer-controlled channels. Afstyla's differentiation must support continued use in patients who value its clinical and operational profile.
Scenario 4: Accelerated non-factor substitution
Hemlibra or future subcutaneous therapies reduce the total factor VIII market faster than biosimilar entry reduces Afstyla's price. This is the more significant long-term category risk.
How does Afstyla compare with Hemlibra and Altuviiio?
| Dimension |
Afstyla |
Hemlibra |
Altuviiio |
| Modality |
Recombinant factor VIII |
Bispecific antibody |
Extended-half-life factor VIII |
| Administration |
Intravenous |
Subcutaneous |
Intravenous |
| Main benefit |
Factor replacement with single-chain stability |
Low-frequency prophylaxis and low infusion burden |
Longer factor VIII dosing intervals |
| Inhibitor use |
Not suitable for active inhibitors |
Approved for patients with and without inhibitors |
Factor VIII replacement |
| Biosimilar risk |
Possible after regulatory and patent barriers |
Biosimilar risk is later and more complex |
Biologic competition and patent risk |
| Commercial threat to Afstyla |
High |
High |
High among factor VIII users |
Key Takeaways
- Afstyla is CSL Behring's recombinant single-chain factor VIII product for hemophilia A.
- Its differentiation is molecular stability and extended pharmacokinetics, not a fundamentally different treatment mechanism.
- Hemlibra is the largest structural threat because it replaces intravenous factor prophylaxis with subcutaneous administration.
- Altuviiio and other extended-half-life factor VIII products create direct competition within the replacement-therapy market.
- Afstyla-specific revenue is not separately disclosed by CSL, preventing a verified product-level revenue forecast.
- The statutory biologic exclusivity period points to a major U.S. exclusivity transition around 2028, subject to the applicable first-licensure calculation.
- Generic competition is unlikely; biosimilar and branded biologic competition are the relevant entry risks.
- Manufacturing complexity and product-specific characterization create meaningful barriers after patent expiry.
- Afstyla's long-term value depends more on franchise retention, payer contracting, and clinical switching patterns than on category growth.
FAQs About Afstyla Market and Patent Risk
Is Afstyla a standard-half-life or extended-half-life factor VIII product?
Afstyla is an extended-half-life recombinant factor VIII product with a single-chain molecular structure and an approximate half-life of 14 to 15 hours, subject to patient-specific variation.
Is Afstyla interchangeable with Hemlibra?
No. Afstyla is intravenous factor VIII replacement, while Hemlibra is a subcutaneous bispecific antibody. They have different mechanisms, dosing schedules, regulatory labels, and monitoring requirements.
Can a generic drug replace Afstyla?
No conventional generic pathway applies. Potential competitors would use the biologic biosimilar pathway or launch different recombinant factor VIII products.
Does Afstyla have an Orange Book patent listing?
Afstyla is a biologic and is not assessed through the conventional small-molecule Orange Book listing framework. Relevant patent rights may appear in USPTO records, litigation filings, licensing documents, and company disclosures.
What is the largest long-term commercial risk for Afstyla?
The largest long-term risk is substitution away from intravenous factor VIII, led by subcutaneous non-factor prophylaxis and newer factor VIII products with longer dosing intervals.
References
-
U.S. Food and Drug Administration. (2016). AFSTYLA (antihemophilic factor [recombinant], single chain) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
CSL Limited. (2023). Annual report 2023. CSL Limited.
-
Roche. (2023). Hemlibra prescribing information. Genentech.
-
Sanofi. (2024). ALTUVIIIO prescribing information. Sanofi.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, ยงยง 7001-7003.
-
World Federation of Hemophilia. (2020). Guidelines for the management of hemophilia (3rd ed.). World Federation of Hemophilia.
